The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma

被引:3
|
作者
Xiang, Xiaoyong [1 ,2 ]
Chen, Peng [1 ,2 ]
Lan, Fengming [1 ,2 ]
Ma, Li [1 ,2 ]
Jin, Jing [1 ,2 ,3 ]
Zhang, Ye [3 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp & Shenzhen Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Shenzhen, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc,Dept Radiat Oncol, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
nasopharyngeal carcinoma; locoregionally advanced; induction chemotherapy; short-term efficacy; PD-1; GROWTH-FACTOR RECEPTOR; CHEMORADIOTHERAPY; MULTICENTER; RADIOTHERAPY; GEMCITABINE; EXPRESSION; PLACEBO; PHASE-3; NPC;
D O I
10.3389/fonc.2023.1110281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThis study aimed to investigate the short-term efficacy and safety of induction chemotherapy (IC) combined with PD-1 inhibitor or anti-EGFR in the treatment of locoregionally advanced nasopharyngeal carcinoma (LA-NPC). Methods and materialsWe retrospectively reviewed the clinical data of 206 patients with LA-NPC, including IC combined with anti-PD-1 (57 patients), IC combined with anti-EGFR (28 patients), and IC alone (121 patients). The short-term efficacy was assessed at the end of IC and one month after overall treatment. According to the RECIST v1.1, the short-term efficacy of cervical lymph nodes and primary nasopharynx foci was divided into complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD). The overall response (ORR) was defined as the sum of CR and PR. Acute toxicities were graded according to the CTCAE v5.0. One-way analysis of variance (ANOVA) was used to compare differences in the numerical variables among groups. Fisher Freeman-Halton test or Pearson Chi-square test was used to compare classified variables. ResultsThe ORR rates of primary nasopharynx foci in IC, anti-EGFR, and anti-PD-1 group were 68.60%, 67.9%, and 94.7%, respectively, and the corresponding rates of ORR in cervical lymph nodes were 78.5%, 71.4%, and 93.0%, respectively. There was a statistical difference in the ORR between the three groups. Further analysis showed that after IC or overall treatment, the CR rate of primary nasopharynx foci in the anti-PD-1 group was significantly higher than the other two groups. The most common adverse effects were hematotoxicity, gastrointestinal toxicity, and transaminase elevation. However, there were no statistical differences in the frequency of any common adverse effects between the three groups. ConclusionsThe addition of anti-PD-1 based on IC significantly improved the short-term efficacy of LA-NPC and toxicities were tolerable.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] The safety and efficacy of gemcitabine and cisplatin (GP)‐based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta‐analysis
    Min Tang
    Zhongxiong Jia
    Ju Zhang
    European Archives of Oto-Rhino-Laryngology, 2022, 279 : 1561 - 1572
  • [22] Anlotinib combined with induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A phase II study.
    Jiang, Feng
    Chen, Xiaozhong
    Liu, Tongxin
    Qin, WeiFeng
    Huang, Shuang
    Cao, Caineng
    Jin, Ting
    Jin, Qifeng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18071 - E18071
  • [23] Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study
    Mu, Xiaoli
    Liu, Hongyan
    Wu, Juan
    Chen, Shi
    Peng, Xingchen
    Wang, Jingjing
    Wei, Zhigong
    He, Ling
    Liu, Jiyan
    Lu, Zejun
    Su, Yonglin
    AGING-US, 2022, 14 (16): : 6727 - 6739
  • [24] Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion
    Zhang, Yufeng
    Zhang, Haiyan
    Xu, Haoqian
    Wang, Ying
    Feng, Long
    Yi, Fengming
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [25] Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma
    Peng, Hao
    Tang, Ling-Long
    Liu, Xu
    Chen, Lei
    Li, Wen-Fei
    Mao, Yan-Ping
    Zhang, Yuan
    Liu, Li-Zhi
    Tian, Li
    Guo, Ying
    Sun, Ying
    Ma, Jun
    CANCER SCIENCE, 2018, 109 (05) : 1609 - 1616
  • [26] Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis
    Wang, Lei
    Lin, Li
    Zhou, Wei
    PHARMACOLOGY & THERAPEUTICS, 2024, 257
  • [27] Efficacy of Lenvatinib Combined with PD-1 Inhibitor versus Sorafenib and PD-1 Inhibitor with or Without TACE for Hepatocellular Carcinoma with
    Duan, Wen-Bin
    Wang, Xiao-Hui
    Zhang, Guo-Can
    He, Zhuo
    Li, Shao-Qiang
    Zhou, Jie
    IMMUNOTARGETS AND THERAPY, 2024, 13 : 247 - 258
  • [28] The efficacy and safety of the addition of programmed cell death protein 1 inhibitor to preoperative chemotherapy in locoregionally advanced oropharyngeal carcinoma
    Lu, Guan-Zhong
    Hong, Zhi-Cong
    Yu, Yi-Feng
    Guo, Lin-Feng
    Ginat, Daniel T.
    Wu, San-Gang
    Guan, Li-Mei
    TRANSLATIONAL CANCER RESEARCH, 2025, 14 (02) : 1401 - 1414
  • [29] The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis
    Tang, Min
    Jia, Zhongxiong
    Zhang, Ju
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2022, 279 (03) : 1561 - 1572
  • [30] Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma
    Lv, Xing
    Xia, Wei-Xiong
    Ke, Liang-Ru
    Yang, Jing
    Qiu, Wen-Zhe
    Yu, Ya-Hui
    Liang, Hu
    Huang, Xin-Jun
    Liu, Guo-Yin
    Zeng, Qi
    Guo, Xiang
    Xiang, Yan-Qun
    ONCOTARGETS AND THERAPY, 2016, 9 : 5123 - 5131